@harsh.beria93 - Is it fair to see Sharda as a Krsnna diagnostic of Agrochem. Having a different business model than the rest within the sector. I am not sure if the rest of the players revenue varies based on the no. of registrations?
Posts in category Value Pickr
Gland Pharma- Generic Injectables (30-07-2022)
Gland - In the concall Mr. Sadu said impact is due to syringe supply constraints, but in Reddys latest concall, they said there is no such issue experienced by them. (It is evident there is huge demand for syringes all over the world for vaccines ) How to understand these kind of statements (in terms of management honesty / integrity ) ?
Question asked in Hitesh bhai’s portfolio thread by @Rafi_Syed @hitesh2710
My thinking
Syringes required for different products are different
Gland uses (as I know famous BD syringes and device)
Some of them are glass syringes for specific measured doses
Some high viscosity medicine are difficult to inject (usually done by support staff) (some time at home)required some locking system and flanges proper holding
All this syringes and devices are preapproved by regulators so you cannot change overnight
Now coming to the Dr Reddy’s concall comment
They have only 15% revenue from injectable(how much prefilled syringes i don’t know) (how much in US market)and maybe having different products, even in previous calls of gland Pharma… Gland is making products for Dr Reddy’s
Just taking small statement out of context and making big on social media (twitter) is trending
personally I take it as personal bias of some analysts
Ultimately time will tell the truth
(Syringes supplied with ampules & muti dose vials are just commodities)
Hitesh portfolio (30-07-2022)
Hi Hitesh Sir, what is your view on sona blw .Q1 FY23 results are somewhat weak due to slow down of economy in Europe and US despite all time high revenue growth .currently it has order book of 10X of FY22 sales and management also seems good .
ValuePickr Pune (29-07-2022)
I’m active from time to time
ValuePickr Pune (29-07-2022)
Is this meeting still happening? Any active members here?
S Chand- Transforming into a Complete Education content provider (29-07-2022)
Valuations are quite personal tbh but just to tell you how I look at it, it is trading 4x market cap to cash flow. The company is reducing its expenses and focusing on better cash conversion. The near term triggers like NCE/NCF Implementation might help the company to grow 20-25% for couple of years from current levels, in this scenario, the bottom line will grow much faster than top line.
While valuing I considered above points and added some margin of safety due to underlying risk and past track records before coming to a right valuations for me(There is no right answer). At the end, it’s a game of probabilities.
Disc: Invested, no recommendations
Pragnesh’s portfolio (29-07-2022)
Adding anup engineering
Zomato – Should you order? (29-07-2022)
Must say I was tempted a little to begin exposure to Zomato in recent plunge but still could not convince myself even after the crash …
The strategy is not clear and decisions too aggressive for my comfort like recent acquisition…
Add to that, the constant news flow where we read that either partner restaurants or delivery agents are not happy or at receiving ends plus no serious player with scale wants to partner with them…either they want to develop their own delivery ecosystem or partner with more economical pure delivery people/companies…
In such case, honestly I do not understand the moat or runway or leadership benefits which other experts see…still on lookout…
Disc. Above thoughts only for academic purposes and I can be wrong in all my assessments.
Gujarat Fluorochemicals: A hidden fluorine story (29-07-2022)
Solvay 2022 first half results.pdf (402.6 KB)
Solvay raises full year guidance following strong performance driven by higher volumes and prices
https://www.solvay.com/en/press-release/solvay-2022-first-half-results